Immunogenicity, safety and clinical outcomes of the SARS-CoV-2 BNT162b2 vaccine in adolescents with type 1 diabetes

INTRODUCTION: The mRNA-based BNT162b2 (Pfizer-BioNTech) vaccine has been shown to elicit robust systemic immune response and confer substantial protection against the severe coronavirus disease (COVID-19), with a favorable safety profile in adolescents. However, no data exist regarding immunogenicit...

Descripción completa

Detalles Bibliográficos
Autores principales: Emeksiz, Hamdi Cihan, Hepokur, Merve Nur, Şahin, Sibel Ergin, Şirvan, Banu Nursoy, Çiçek, Burçin, Önder, Aşan, Yıldız, Metin, Aksakal, Derya Karaman, Bideci, Aysun, Ovalı, Hüsnü Fahri, İşman, Ferruh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331611/
https://www.ncbi.nlm.nih.gov/pubmed/37435175
http://dx.doi.org/10.3389/fped.2023.1191706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331611/
https://www.ncbi.nlm.nih.gov/pubmed/37435175
http://dx.doi.org/10.3389/fped.2023.1191706

Ejemplares similares